- You can view the full Pfizer Ratings Report.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading up 108 points (+0.7%) at 14,767 as of Tuesday, Jun 25, 2013, 10:35 a.m. ET. During this time, 198.5 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 609.1 million. The NYSE advances/declines ratio sits at 1,890 issues advancing vs. 963 declining with 99 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass. Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with a four-cent decline (-0.1%) bringing the stock to $27.67. Volume for Pfizer currently sits at 54.9 million shares traded vs. an average daily trading volume of 52 million shares. Pfizer has a market cap of $201.09 billion and is part of the health care sector and drugs industry. Shares are up 10.5% year to date as of Monday's close. The stock's dividend yield sits at 3.4%. Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people worldwide. The company has a P/E ratio of 20.2, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.